BIO-TECHNE CORP shareholders Q3 2023

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Hills Bank & Trust Co 18,532$1,261,4730.15%
S&CO INC 26,380$1,7950.15%
L. Roy Papp & Associates, LLP 15,875$1,080,6120.15%
Cherry Creek Investment Advisors, Inc. 3,072$209,1260.14%
Power Corp of Canada 32,867$2,237,2570.14%
Railway Pension Investments Ltd 190,200$12,946,9140.14%
SVB WEALTH LLC 93,804$6,385,2120.14%
OMERS ADMINISTRATION Corp 135,807$9,244,3820.14%
Zions Bancorporation, N.A. 23,328$1,587,9370.14%
Allspring Global Investments Holdings, LLC 1,139,195$77,545,1000.14%
First City Capital Management, Inc. 3,100$211,0170.13%
SRS Capital Advisors, Inc. 14,107$960,2310.12%
FOX RUN MANAGEMENT, L.L.C. 5,898$401,4770.12%
VAN STRUM & TOWNE INC. 4,000$272,2800.12%
NAPLES GLOBAL ADVISORS, LLC 14,000$952,9800.12%
FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ 218,918$14,901,7480.11%
LMCG INVESTMENTS, LLC 23,768$1,617,8880.11%
Legacy Advisors, LLC 9,601$653,5400.10%
STEPH & CO 2,696$183,5170.10%
V-Square Quantitative Management LLC 3,453$235,0460.10%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q3 2023. To view BIO-TECHNE CORP's shareholder history, click here.